(redirected from multiple drug resistance)
Also found in: Dictionary, Thesaurus, Medical, Legal, Encyclopedia, Wikipedia.


An effective upper bound on prices achieved because of many willing sellers at that price level.

Resistance Level

In technical analysis, a price that a security does not, or only rarely, rise above. Technical analysts identify a resistance level by looking at past performance. When the security approaches the resistance level, it is seen as an indication to sell the security, which will increase the supply, causing the security's price to fall back below the resistance level. If there are too many buyers, however, the security rises above the resistance level. When this occurs, the price of the security will likely continue to rise until it finds another resistance level. It is also called the overhead resistance level. See also: Price ceiling, Support (Support level).


An increased supply of a security. Compare support.


Resistance, or resistance level, is the top of a stock's current trading range, and the point at which the price is higher than investors are willing to pay. As stockholders sell at resistance level, the stock price goes down because supply exceeds demand.

For example, if, on a repeated basis, as stock A's price reaches $60, stockholders begin to sell, then $60 is considered its resistance level. But a trading range isn't fixed and investor attitudes change, so the resistance level tends to move higher or lower over time.

If stock A rises to $63 without a surge of selling, the current resistance line has been breached. This may be the result of a rising market or a bullish assessment of the stock's value. On the other hand, if selling increases at $57, that may become the new resistance level.

Conversely, the level at which demand exceeds supply and investors typically buy a certain stock is called support. It's the point that's considered the bottom of a stock's current trading range.

Technical analysts use the concepts of resistance and support in anticipating future stock price movements.

References in periodicals archive ?
By comparing PhenoSense results with data on the patients' treatment histories, the researchers were able to identify factors likely to lead to multiple drug resistance, including longer treatment experience, prior non-nucleoside reverse transcriptase inhibitor (NNRTI) use, and greater number of protease inhibitors used.
In in vivo testing TPI 287 demonstrated greater tumor growth inhibition activity in tumor cell lines with multiple drug resistance, MDR1.
Additionally, it has demonstrated, both in vitro and in vivo, an ability to overcome multiple drug resistance (MDR) in various tumor models.
These new antibiotics will improve the morality and morbidity caused by a wide variety of pathogenic microorganisms, especially those that have exhibited multiple drug resistance.
Some estimate the number of people living with multiple drug resistance at 64,000 in the United States, many of who have gone through at least four HIV medication regimens already.
Specifically, in tumor cell lines with multiple drug resistance, or MDR1, TPI 287 had better efficacy in shrinking tumor volume when compared to paclitaxel in breast cancer, docetaxel in prostate and non-small cell lung cancers, and similar to irinotecan in colon cancer.
Additionally, it has demonstrated in vitro and in vivo activity in multiple drug resistance (MDR) tumor models.

Full browser ?